Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Deanna Kamienski

Senior Deals Analyst, Strategic Transactions

Deanna has been with Strategic Transactions since 2000. In her role she researches, analyzes, and writes summaries of alliances, M&A, and fundraising activities among global biopharma and medtech companies. Deanna oversees the two Dealmaking columns and authors a Quarterly Statistics article, in addition to contributing content to In Vivo. Prior to joining Strategic Transactions, Deanna worked at Yale University, first in the Office of Medical Development as a gift support services coordinator assisting in fundraising activities and producing fund reports and donor gift acknowledgements. Later she worked at Yale's Department of Epidemiology and Public Health as a research assistant performing various tasks including editing the School of Public Health's website, identifying new funding prospects, providing grant support for the Dean, and preparing development materials and reports. Deanna holds a Bachelor of Science degree from the University of Vermont. In her spare time she enjoys boating and fishing with her family and friends.
Advertisement
Set Alert for Articles By Deanna Kamienski

Latest From Deanna Kamienski

Tech Transfer Roundup: Ohio State Turns To Industry Exec To Optimize Assets Before A Deal

Jeffrey Patrick joins Ohio State's effort to develop cancer drugs from internal research, bringing a biopharma viewpoint to optimizing such programs before the deal-making effort starts. Plus, the EMA sets a framework for academic interaction, and more tech transfer news.

Deals StartUps and SMEs

Deals Shaping The Medical Industry, April 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2017.

Deals BioPharmaceutical

Venture Funding Deals: LAM Nabs $58m Series C One Year After $40m Round

Also, Advicenne doubles its fundraising to date; Michael Gilman-helmed Arrakis raises a $38m Series A; Breath spins out with $46m; and Spero gets $51.7m for novel antibacterials.

Commercial StartUps and SMEs

Deals Shaping The Medical Industry, March 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2017.

Deals BioPharmaceutical

Venture Funding Deals

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in January and February 2017.

Commercial StartUps and SMEs

Tech Transfer Roundup: Repeat Business As Boehringer, Vanderbilt Collaborate Further On KRAS

This month's roundup also records a second tie-up between Florida State and Spotlight Innovations, while Taiwan's Lin Biosciences licenses global rights to a CDC7 kinase inhibitor from Columbia and Memorial Sloan Kettering.

Deals StartUps and SMEs
See All
Advertisement
UsernamePublicRestriction

Register